select by a global government R&D program by KHIDI

MOU signed with AJOU MBD T2B Center

Change of name to GENIXCUR Inc.

Filed 4 patents of AI-based cell-specific peptides & AAVs (featuring 60 vectors)

Made a presentation of GXC-301(Lafora disease) preclinical data at 2023 Lafora Disease Science Symposium in Bologna, Italy

Filed a patent application for GXC301, a therapeutic agent for Lafora disease

Filed a patent applicaion for INSIGHTMINER, an AI-driven AAV Engineering platform

aMCI biomarker patent application

Made a presentation of an AAV program at ISCT 2023 in Paris (Collaborative research with Samsung Seoul Hospital)

Signed MOUs with Kyungdong Pharmaceutical Co., Ltd. for GMP CDMO and L/O

Signed Research and Development Agreement with ToolGen

Inno-Biz Certification (Minister of Small and Medium Venture Business)

Participation in R&D projects to foster research-oriented hospitals (supervisor: Samsung Seoul Hospital)

Series A fundraising

TF launched for InsightMiner 1.0

Signed a MOU with MedySapiens

GXC101 funded by a government R&D program by KHIDI

GXC301 funded by a government R&D program by Ministry of SMEs and Startups

Awarded ‘Appreciation of Technology Commercialization & Entrepreneurship’ from Ministry of Health and Welfare

GXC101 funded 1M by a government R&D program by Ministry of Health and Welfare

Certification of venture companies

GXC-101 patent registered in the US

Certification of corporate research institutes

GXC-101 in licensing from IBS & DGIST

Founded